X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (532) 532
Publication (70) 70
Book Review (13) 13
Book Chapter (8) 8
Conference Proceeding (2) 2
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (353) 353
humans (347) 347
elvitegravir (324) 324
hiv infections - drug therapy (259) 259
infectious diseases (240) 240
double-blind (232) 232
raltegravir (199) 199
hiv (181) 181
pharmacology & pharmacy (179) 179
initial treatment (158) 158
co-formulated elvitegravir (156) 156
hiv-1 - drug effects (131) 131
emtricitabine (129) 129
cobicistat (124) 124
hiv infections - virology (124) 124
male (123) 123
immunology (122) 122
dolutegravir (117) 117
female (117) 117
adult (110) 110
anti-hiv agents - therapeutic use (103) 103
antiretroviral therapy (100) 100
virology (100) 100
tenofovir (98) 98
hiv integrase inhibitors - pharmacology (97) 97
microbiology (96) 96
infection (91) 91
antiviral agents (87) 87
integrase (85) 85
middle aged (85) 85
human immunodeficiency virus--hiv (78) 78
hiv infection (77) 77
non-inferiority trial (77) 77
drug resistance, viral (76) 76
hiv-1 - genetics (75) 75
pharmacokinetics (73) 73
tenofovir disoproxil fumarate (70) 70
anti-hiv agents - administration & dosage (69) 69
hiv integrase inhibitors - therapeutic use (67) 67
mutation (67) 67
treatment outcome (67) 67
aids/hiv (65) 65
once-daily dolutegravir (65) 65
resistance (65) 65
drug therapy (63) 63
drug combinations (61) 61
hiv-1 (61) 61
integrase inhibitors (61) 61
drug resistance (60) 60
adenine - analogs & derivatives (59) 59
hiv integrase - genetics (57) 57
anti-hiv agents - adverse effects (55) 55
disoproxil fumarate (54) 54
quinolones - therapeutic use (54) 54
anti-hiv agents - pharmacology (53) 53
antiretroviral drugs (53) 53
efavirenz (53) 53
raltegravir potassium (53) 53
hiv-1 infection (52) 52
open-label (52) 52
therapy (47) 47
integrase inhibitor (46) 46
quinolones - pharmacology (46) 46
safety (46) 46
drug interactions (45) 45
hiv integrase - metabolism (45) 45
efficacy (44) 44
highly active antiretroviral therapy (44) 44
hiv-1 - enzymology (44) 44
analysis (43) 43
phase-3 (43) 43
viral load (43) 43
antiretroviral-naive adults (42) 42
drug therapy, combination (41) 41
treatment-experienced patients (41) 41
research (40) 40
tenofovir alafenamide (39) 39
cross-resistance (38) 38
quinolones - administration & dosage (38) 38
heterocyclic compounds, 3-ring - therapeutic use (37) 37
in-vitro (37) 37
ritonavir (37) 37
aids (36) 36
drug-resistance (36) 36
heterocyclic compounds, 3-ring - pharmacology (36) 36
young adult (36) 36
adenine - therapeutic use (35) 35
hiv-1 integrase (35) 35
twice-daily raltegravir (35) 35
care and treatment (34) 34
hiv-infected patients (34) 34
animals (33) 33
antiretroviral agents (33) 33
dosage and administration (33) 33
health aspects (33) 33
non-inferiority (33) 33
pyrrolidinones - pharmacology (33) 33
quinolones - pharmacokinetics (33) 33
treatment-naive (33) 33
mutations (32) 32
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 11/2014, Volume 70, Issue 6, pp. 1865 - 1873
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 4/2011, Volume 50, Issue 4, pp. 229 - 244
Journal Article
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, ISSN 1742-5255, 03/2015, Volume 11, Issue 3, pp. 427 - 435
Introduction: Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir (EVG/COBI/FTC/TDF or Stribild (TM)) is the latest antiretroviral tablet... 
INFECTION ANALYSIS | COFORMULATED ELVITEGRAVIR | Stribild | elvitegravir | BIOCHEMISTRY & MOLECULAR BIOLOGY | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | OPEN-LABEL | cobicistat | IN-VITRO | REGIMEN ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DF | HIV | DISOPROXIL FUMARATE | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2017, Volume 12, Issue 6, p. e0179254
Objectives The study aim was to evaluate the impact on Liver and Kidney toxicity of the single tablet regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir... 
REVERSE-TRANSCRIPTASE INHIBITOR | PATIENT-REPORTED SYMPTOMS | COFORMULATED ELVITEGRAVIR | MULTIDISCIPLINARY SCIENCES | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | OPEN-LABEL | HIV-1 INFECTION | BOOSTED PROTEASE INHIBITOR | PHASE 3B | Emtricitabine - therapeutic use | Tenofovir - therapeutic use | HIV-1 - drug effects | HIV Infections - virology | Humans | Middle Aged | Male | Maximum Tolerated Dose | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Cobicistat - therapeutic use | Safety | Drug Combinations | Antiviral agents | Complications and side effects | Dosage and administration | Kidney failure | Research | Risk factors | Slopes | Therapy | Toxicity | Liver | Transaminase | Chronic infection | Viruses | Infections | Tenofovir | Ethics | Hepatitis | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Quality | Human immunodeficiency virus--HIV | Emtricitabine | Antiretroviral drugs | Alanine | Filtration | Kidneys | Epidermal growth factor receptors | Patients | Antiretroviral therapy | Glomerular filtration rate | Studies | Infectious diseases | Hospitals | Surveillance | Alanine transaminase | Aspartate aminotransferase | Kidney transplantation | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 05/2015, Volume 4, Issue 3, pp. 218 - 225
This randomized, two‐way crossover study evaluated the bioavailability of elvitegravir administered as the new individual tablet containing 150 mg and a... 
HIV integrase strand transfer inhibitor | Japanese | elvitegravir | bioequivalence | stribild | Elvitegravir | Bioequivalence | Stribild | INTEGRASE | EMTRICITABINE | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | TOXIN EXTRUSION 1 | HUMAN MULTIDRUG | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | HIV-1 INFECTION | TENOFOVIR | Tablets | Area Under Curve | Humans | Middle Aged | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects | Male | Metabolic Clearance Rate | Healthy Volunteers | Anti-HIV Agents - administration & dosage | Young Adult | Quinolones - adverse effects | Quinolones - pharmacokinetics | Adult | Drug Therapy, Combination | Drug Administration Schedule | Administration, Oral | Anti-HIV Agents - adverse effects | Japan | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Cobicistat - administration & dosage | Cross-Over Studies | Quinolones - administration & dosage | Cobicistat - pharmacokinetics | Models, Biological | Anti-HIV Agents - pharmacokinetics | Least-Squares Analysis | Cobicistat - adverse effects | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacokinetics | Therapeutic Equivalency
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 96 - 100
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs... 
HIV | cobicistat | phase 3 randomized trial | safety | efficacy | stribild | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | PHASE-3 | IMMUNOLOGY | TREATMENT-NAIVE | EFAVIRENZ | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Humans | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Male | RNA, Viral - blood | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | HIV-1 - physiology | Quinolones - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Oxazines - adverse effects | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Oxazines - therapeutic use | Creatinine - blood | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 07/2018, Volume 156, pp. 163 - 169
A liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of tenofovir and tenofovir... 
Tenofovir | Plasma | Cerebrospinal fluid | Tenofovir alafenamide | Mass spectrometry | CHEMISTRY, ANALYTICAL | LABELED INTERNAL STANDARDS | ELVITEGRAVIR | EMTRICITABINE | IMPLEMENTATION | HUMAN-IMMUNODEFICIENCY-VIRUS | TANDEM MASS-SPECTROMETRY | REVERSE-TRANSCRIPTASE INHIBITOR | PHARMACOKINETICS | PRODRUG | PHARMACOLOGY & PHARMACY | SIMULTANEOUS QUANTIFICATION | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - analysis | HIV Infections - blood | HIV Infections - cerebrospinal fluid | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Emtricitabine - therapeutic use | Reproducibility of Results | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Adenine - analysis | Chromatography, High Pressure Liquid | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Adenine - therapeutic use | Emtricitabine - analysis | Tenofovir - analogs & derivatives | Quinolones - analysis | Quinolones - therapeutic use | Solid Phase Extraction | Tenofovir - analysis | Cobicistat - analysis | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Combinations | Antiviral agents | Ionization | Analysis | Pharmacy | Formic acid | Nitriles | Liquid chromatography | Organic acids | mass spectrometry | tenofovir alafenamide | plasma | tenofovir | cerebrospinal fluid
Journal Article